Regulation of Aseptic Processing in the 21st Century - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulation of Aseptic Processing in the 21st Century
The authors question certain aspects of the industry's current regulatory-compliance strategy and suggest that aseptic-process control and evaluation should be revised.


Pharmaceutical Technology
Volume 35, pp. s46-s50

References

1. FDA, Sterile Drug Products Produced by Aseptic Processing (Rockville, MD, Jun. 1987).

2. FDA, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practices (Rockville, MD, Sep. 2004).

3. EMA, Annex 1, Sterile Medicinal Products (London, 2009).

4. Task Force on Sterile Drug Products Produced by Aseptic Processing, (with support from the Japanese Ministry of Health, Labor, and Welfare), Guidance for Industry—Sterile Drug Products Produced by Aseptic Processing, (Tokyo, 2005).

5. J. Agalloco and J. Akers, Pharm. Technol. 30 (7), 60–76 (2006).

6. M. Miller and M. Walsh, PDA Annual Meeting (Las Vegas, 2009).

7. International Standards Organization, Standards 14644-1 to 8: Clean Rooms and Associated Controlled Environments (Geneva, 1999).

8. B. Reinmuller, Building Services Engineering, Bulletin 56, (Royal Institute of Technology, Stockholm, 2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here